Jeremy R Graff Selected Research

Eukaryotic Initiation Factor-4E

1/2016	Cotargeting MNK and MEK kinases induces the regression of NF1-mutant cancers.
1/2016	Phosphorylation of eIF4E serine 209 is associated with tumour progression and reduced survival in malignant melanoma.
5/2013	Inhibition of Mnk kinase activity by cercosporamide and suppressive effects on acute myeloid leukemia precursors.
1/2013	Targeting eukaryotic translation in mesothelioma cells with an eIF4E-specific antisense oligonucleotide.
3/2011	Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases.
12/2010	Modulation of 4E-BP1 function as a critical determinant of enzastaurin-induced apoptosis.
5/2009	eIF4E activation is commonly elevated in advanced human prostate cancers and significantly related to reduced patient survival.
8/2008	Targeting the eIF4F translation initiation complex for cancer therapy.
2/2008	Targeting the eukaryotic translation initiation factor 4E for cancer therapy.
9/2007	Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jeremy R Graff Research Topics

Disease

21	Neoplasms (Cancer) 01/2022 - 01/2003
6	Neoplasm Metastasis (Metastasis) 01/2022 - 01/2003
4	Carcinoma (Carcinomatosis) 12/2010 - 09/2003
3	Prostatic Neoplasms (Prostate Cancer) 05/2009 - 02/2002
3	Disease Progression 08/2008 - 04/2004
3	Carcinogenesis 02/2008 - 02/2002
3	Adenocarcinoma 09/2003 - 02/2002
2	Colonic Neoplasms (Colon Cancer) 01/2022 - 08/2005
2	Melanoma (Melanoma, Malignant) 01/2016 - 02/2014
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 02/2014 - 11/2004
2	Glioblastoma (Glioblastoma Multiforme) 12/2010 - 08/2005
1	Lung Neoplasms (Lung Cancer) 01/2022
1	Experimental Melanoma 01/2022
1	Glioma (Gliomas) 02/2014
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 05/2013
1	Mesothelioma 01/2013
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 12/2010
1	B-Cell Lymphoma (Lymphoma, B Cell) 12/2010
1	Prostatic Hyperplasia (Benign Prostatic Hyperplasia) 05/2009
1	Body Weight (Weight, Body) 09/2007
1	Breast Neoplasms (Breast Cancer) 01/2006
1	Urinary Bladder Neoplasms (Bladder Cancer) 01/2006
1	Transitional Cell Carcinoma 11/2004
1	Renal Cell Carcinoma (Grawitz Tumor) 11/2004
1	Colorectal Neoplasms (Colorectal Cancer) 05/2004
1	Prostatic Intraepithelial Neoplasia 02/2002

Drug/Important Bio-Agent (IBA)

12	Eukaryotic Initiation Factor-4EIBA 01/2016 - 01/2003
7	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2003
6	Peptide Initiation Factors (Initiation Factor)IBA 01/2016 - 09/2007
4	Phosphotransferases (Kinase)IBA 01/2016 - 03/2011
4	Messenger RNA (mRNA)IBA 01/2013 - 01/2003
3	Prostaglandins GIBA 01/2022 - 01/2016
3	Eukaryotic Initiation Factor-4F (EIF4F)IBA 01/2013 - 01/2003
3	AndrogensIBA 05/2009 - 02/2002
3	Cyclin D1IBA 08/2008 - 01/2003
2	AntibodiesIBA 01/2022 - 01/2016
2	LigandsIBA 01/2022 - 08/2013
2	Pharmaceutical PreparationsIBA 02/2014 - 01/2013
2	Antisense OligonucleotidesIBA 01/2013 - 05/2009
2	enzastaurinIBA 12/2010 - 08/2005
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 09/2007 - 01/2003
2	Transforming Growth Factor-beta Type I ReceptorIBA 01/2006 - 11/2004
2	Transforming Growth Factor beta (TGF-beta)IBA 01/2006 - 11/2004
1	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 01/2022
1	Programmed Cell Death 1 ReceptorIBA 01/2022
1	Immune Checkpoint InhibitorsIBA 01/2022
1	Monophenol Monooxygenase (Tyrosinase)IBA 01/2022
1	Complement System Proteins (Complement)IBA 01/2022
1	Interferon Type IIBA 01/2022
1	GlucansIBA 01/2016
1	cabozantinibIBA 01/2016
1	Pathogen-Associated Molecular Pattern MoleculesIBA 01/2016
1	Mechanistic Target of Rapamycin Complex 1IBA 01/2016
1	Antigen-Antibody Complex (Immune Complex)IBA 01/2016
1	Complement Receptors (Complement Receptor)IBA 01/2016
1	Serine (L-Serine)FDA Link 01/2016
1	Biomarkers (Surrogate Marker)IBA 01/2016
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2016
1	ChemokinesIBA 01/2016
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2016
1	MAP Kinase Kinase Kinases (MAP Kinase Kinase Kinase)IBA 01/2016
1	Neurofibromin 1 (Neurofibromin)IBA 01/2016
1	ralimetinibIBA 02/2014
1	Mitogen-Activated Protein KinasesIBA 02/2014
1	p38 Mitogen-Activated Protein KinasesIBA 02/2014
1	Adenosine Triphosphate (ATP)IBA 08/2013
1	Oncogene Proteins (Oncogene Protein)IBA 08/2013
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 08/2013
1	tyrosine receptor (receptor, tyrosine)IBA 08/2013
1	c-Mer Tyrosine KinaseIBA 08/2013
1	merestinibIBA 08/2013
1	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 08/2013
1	cercosporamideIBA 05/2013
1	Pemetrexed (MTA)FDA Link 01/2013
1	Gemcitabine FDA Link 01/2013
1	AgarIBA 03/2011
1	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 02/2008
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 09/2007
1	Transaminases (Aminotransferases)IBA 09/2007
1	Transforming Growth Factor beta Receptors (TGF beta Receptors)IBA 01/2006
1	Glycogen Synthase Kinase 3 betaIBA 08/2005
1	Protein Kinases (Protein Kinase)IBA 08/2005
1	Protein Kinase C-alphaIBA 11/2004
1	Antisense RNA (Anti-Sense RNA)IBA 04/2004
1	Carrier Proteins (Binding Protein)IBA 04/2004
1	Estrogen Receptor alphaIBA 09/2003
1	Estrogen Receptor betaIBA 09/2003
1	Androgen Receptors (Androgen Receptor)IBA 09/2003
1	trioxifeneIBA 09/2003
1	Selective Estrogen Receptor Modulators (SERM)IBA 09/2003
1	RNA Cap-Binding Proteins (Cap Binding Protein)IBA 01/2003
1	Secretory Phospholipases A2IBA 02/2002
1	Group II Phospholipases A2IBA 02/2002

Therapy/Procedure

10	Therapeutics 01/2016 - 05/2004
1	Immunotherapy 01/2022
1	Drug Therapy (Chemotherapy) 02/2014